7.19.10
Tobira IAC Oral Presentation –TBR-652, A Potent Dual Chemokine Receptor 5/Chemokine Receptor 2 (CCR5/CCR2) Antagonist in Phase 2 Development for Treatment of HIV Infection

7.19.10
Tobira IAC Press Release - TOBIRA’S NEXT-GENERATION ONCE-DAILY CCR5/CCR2 ANTAGONIST DEMONSTRATES POTENT CCR2 INHIBITION, ANTIVIRAL ACTIVITY, SAFETY AND TOLERABILITY IN TREATMENT-EXPERIENCED PATIENTS WITH HIV; TBR-652 Phase IIa Data Presented at XVIII International AIDS Conference Showcase Potentially Important Anti-Inflammatory Benefits

2.17.10
PHARMACOKINETIC/PHARMACODYNAMIC DATA SUPPORT FURTHER DEVELOPMENT OF TOBIRA’S
NEXT-GENERATION CCR5 RECEPTOR ANTAGONIST

2.17.10
TOBIRA’S NEXT-GENERATION ONCE-DAILY CCR5 RECEPTOR ANTAGONIST DEMONSTRATES EFFICACY, SAFETY AND TOLERABILITY IN TREATMENT-EXPERIENCED PATIENTS WITH HIV

2.17.10
Tobira CROI Poster 2010: Pharmacokinetics (PK) and Pharmacodynamics (PD) of TBR-652, A Chemokine Receptor 5 (CCR5) Antagonist, In HIV-1-Infected, Antiretorviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients

11.12.09
Tobira Therapeutics Inc. Announce Presentation of TBR-652 Data at European AIDS Conference

9.18.09
Tobira ICAAC 2009 Poster -TBR-652, A CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST, DEMONSTRATES GOOD ORAL BIOAVAILABILITY AND DESIRABLE PHARMACOKINETIC (PK) AND SAFETY PROFILES IN HEALTHY VOLUNTEERS

9.18.09
Tobira ICAAC 2009 Poster - IN VITRO ANTI-HIV EFFICACY OF THE CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST TBR-652 IN COMBINATION WITH FOUR OTHER CLASSES OF ANTIRETROVIRAL AGENTS

7.22.09
Tobira IAS 2009 Poster - Effect of Food on the Relative Bioavailabiliy and Pharmacokinetics of TBR652

7.22.09
Tobira IAS 2009 Poster 2 - Pharmacokinetics, Safety and Tolerabilityof Single Doses of TBR652 in Healthy Volunteers

7.22.09
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

6.4.09
Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board

4.8.09
Tobira Therapeutics Inc. Initiates Proof of Concept Study with TAK-652 for the Treatment of HIV

9.18.08
In September 2008, Tobira Therapeutics and Kureha Corporation entered into an exclusive evaluation agreement to evaluate KRH-3166, a CXCR4 antagonist in the treatment of HIV-1 infection.  CXCR4 is a human chemokine receptor shown to be required for infection by human immunodeficiency virus (HIV).   KRH-3166 is a pro-drug to KRH-3153 and KRH-3140. Tobira has exclusive rights to evaluate and select a lead compound over the course of two years.  The CXCR4 antagonist provides an additional mechanism of action to combat HIV.

8.18.08
Tobira Therapeutics Inc. Receives US Patent for TBR-652

6.30.08
Tobira Therapeutics Inc. Announces Senior Management Team Senior management team possessing over 130 years of cumulative expertise